Comparative Pharmacology
Head-to-head clinical analysis: CILOSTAZOL versus ENSACOVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CILOSTAZOL versus ENSACOVE.
CILOSTAZOL vs ENSACOVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective phosphodiesterase 3 (PDE3) inhibitor, leading to increased intracellular cAMP in platelets and vascular smooth muscle, resulting in inhibition of platelet aggregation and vasodilation.
Voretigene neparvovec is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
100 mg orally twice daily.
Oral: 200 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 11-13 hours (range 10-15 h) in healthy subjects; prolonged in severe renal impairment (CrCl <25 mL/min) to 20-25 h, and in hepatic impairment.
Clinical Note
moderateCilostazol + Torasemide
"The serum concentration of Torasemide can be increased when it is combined with Cilostazol."
Clinical Note
moderateCilostazol + Tranilast
"Cilostazol may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateCilostazol + Resveratrol
"Cilostazol may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateCilostazol + Etoricoxib
"The serum concentration of Etoricoxib can be increased when it is combined with Cilostazol."
Terminal half-life 20-24 hours, allowing once-daily dosing
Primarily hepatic metabolism via CYP3A4 and CYP2C19; 74% excreted in urine (30% as unchanged drug and 44% as metabolites) and 20% in feces via bile.
Renal: 85% unchanged; biliary/fecal: 10% as metabolites; 5% other
Category D/X
Category C
Phosphodiesterase Inhibitor
Phosphodiesterase Inhibitor